COMPANY

BioVie

Keywords: neurology Long COVID Parkinsons Disease Ascites Decompensated Cirrhosis Alzheimer Disease Parkinson Disease Cirrhosis Ascites Hepatic NE3107

Profile checked Oct 10, 2026

$21.9MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Aug 11, 2025 Raise Follow-on offering: $12M (total, as published), announced Aug 11, 2025. Source: company release on GlobeNewswire. source ↗
Apr 29, 2025 Trial start Phase 2: NE3107 in Adults With Neurological Symptoms of Long COVID source ↗
Mar 26, 2025 Trial start Phase 2: A Study of NE3107 in Early Parkinson's source ↗
Oct 29, 2024 Raise Follow-on offering — Registered direct: $3.24M (total, as published), announced Oct 29, 2024. Source: SEC filing. source ↗
Oct 22, 2024 Raise Follow-on offering — Registered direct: $6.66M (total, as published), announced Oct 22, 2024. Source: SEC filing. source ↗
Jan 4, 2022 Trial start Phase 1/Phase 2: NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa source ↗
Aug 5, 2021 Trial start 3: A Phase 3 Study of NE3107 in Probable Alzheimer's Disease source ↗
Jun 17, 2021 Trial start Phase 2: A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites source ↗
Jul 15, 2017 Trial start Phase 2: Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites source ↗

Funding

Raised: $21.9M. Last 2 years.

Aug 11, 2025 Follow-on offering: $12M (total, as published), announced Aug 11, 2025. Source: company release on GlobeNewswire. source ↗
Oct 29, 2024 Follow-on offering — Registered direct: $3.24M (total, as published), announced Oct 29, 2024. Source: SEC filing. source ↗
Oct 22, 2024 Follow-on offering — Registered direct: $6.66M (total, as published), announced Oct 22, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT06847191	NE3107 in Adults With Neurological Symptoms of Long COVID	Phase 2	Completed	Apr 29, 2025	Aug 6, 2026 (actual)
NCT06757010	A Study of NE3107 in Early Parkinson's	Phase 2	Completed	Mar 26, 2025	May 1, 2026 (actual)
NCT04112199	A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites	Phase 2	Terminated	Jun 17, 2021	May 8, 2023 (actual)
NCT04669028	A Phase 3 Study of NE3107 in Probable Alzheimer's Disease	3	Completed	Aug 5, 2021	Sep 30, 2023 (actual)
NCT05083260	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	Phase 1/Phase 2	Completed	Jan 4, 2022	Nov 21, 2022 (actual)
NCT03107091	Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites	Phase 2	Completed	Jul 15, 2017	Apr 1, 2019 (actual)